In PR+ERα+ breast, endometrial, and ovarian cancer cell lines, high doses of the progestin R5020 upregulated PR expression at the transcriptional and translational levels and the effect was reversed by the addition of the antagonist RU 486 (Diep et al., 2016). Here, PGR is linked to ovarian carcinoma.